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Conclusions: Several low and high risk factors were 
identified which may assist with tailoring future clinical trial 
QA. RTR are essential due to a baseline level of resubmission, 
which is independent of clinician or site factors. There is a 
scope for modifying RTR QA to include only contouring RTR 
submissions at high volume sites. The lower rate of 
resubmission for cases using IMRT may be a surrogate for 
advanced technology implementation at a particular site. 
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Purpose/Objective: Our Center acquired a mobile electron 
linear accelerator for intraoperative radiation therapy (IORT) 
and the clinical activity started at the end of June 2012. The 
risk assessment performed before the start of clinical activity 
was integrated with a predictive matrix risk analysis (FMECA). 
Two years later an analysis of all the relevant criticalities 
was performed in order to improve quality. The aim of this 
study is to present the results of the method elaborated by 
our Working Group and the application of FMECA prospective 
approach to IORT procedure. 
Materials and Methods: A multidisciplinary Working Group 
was created, including different professional profiles. Each 
member of the Working Group was asked to identify a priori 
the criticalities he/she could meet in the process steps 
concerning his/her specific activity. In this way a list of all 
potential failure modes (FM) occuring in each process step 
was drafted. 
The risk analysis was completed by asking the members of 
the team to evaluate the Risk priority number (RPN) of each 
FM.  
Two years after the beginning of IORT clinical activity, the 
risk analysis was repeated by the Working Group, in order to 
assess the improvement achieved. 
Results: The IORT process was subdivided in 43 steps and 39 
criticalities were identified by the Working Group. They 
represented the issues prospectively investigated according 
to the FMECA method. An Excel worksheet was created, 
inserting in rows: process step, professional figures involved, 
failure mode, potential effects of failure, potential causes of 
failure, preliminary RPN and corrective actions. In the re-
analysis of the process - two years later - the final RPN was 
elaborated and the risk reduction (RR) (preliminary RPN – 
final RPN) was also calculated, in order to assess the weight 
of the corrective measures. The highest score was attributed 
to the misalignement of the internal shield, used to protect 
the underlying normal tissues, with a risk reduction equal to 
20 (25%) after corrective actions. The next critical scores 
were related to the inaccurate placement of the applicator in 
the tumour bed (RR: 28; 43,8%) and the wrong definition of 
the CTV (RR: 48; 75%). Another relevant failure mode was the 
inadequate placement of the dosimeter (gafchromic film) on 
top of the internal shield. In most cases this risk was 
prevented following the 'in vivo dosimetry' Procedure, 
elaborated by our Medical Physicist (RR: 28; 46.7%).  
Conclusions: The FMECA technique has provided a 
prospective systematic method for discovering potential 
failures in IORT procedure; evaluating not only the frequency 
of FM but also their severity and detectability, it has given a 
more complete assessment of the risks. It contributes 
therefore to optimize patient safety right from the start of 
our clinical activity and to improve risk management culture 
among all the professionals involved in the Working Group. 
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Purpose/Objective: The North West area has one of the 
largest number of lung cancer patients in the U.K. Data 
collected for these patients relating to treatment outcome 
and graded toxicities does not currently allow us to 
accurately assess these data. In conjunction with a radiation 
oncology professor and a research fellow, an RTT has been 
heavily involved in the definition, production and design of a 
defined, auditable dataset for lung cancer patients. 
Materials and Methods: Our institution is attempting to 
implement a data warehouse product into its information 
technology structure in order to make information more 
accessible to staff conducting audit and research. In the 
baseline assessments made during the set up of the data 
warehouse, the chair of radiation oncology appraised the 
data collected for patients and a decision was made to 
improve the quantity, and more importantly, the quality of 
the data recorded. On a disease site specific basis, and 
beginning with lung (a large patient group with poor 
outcomes), a work stream was set up in order to define an 
